SMALL LYMPHOCYTIC LYMPHOMA

This study is testing whether giving two different pneumonia vaccines in a series works better to build immune protection in adults with chronic lymphocytic leukemia (CLL). CLL weakens the immune system, making patients more likely to get serious infections like pneumonia. Resear…

This study is testing whether the drug mosunetuzumab, given alone or with other leukemia medications, can eliminate tiny amounts of remaining cancer cells in patients with chronic lymphocytic leukemia. The goal is to achieve 'undetectable minimal residual disease' - meaning no de…

This study is testing whether starting a two-drug treatment early, before patients show symptoms, leads to better survival for people with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It will compare early treatment to the current standard of …

This study is testing whether adding a new immunotherapy drug (epcoritamab) to a standard two-drug treatment can lead to better and longer-lasting results for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if this …

This study is testing a new oral medication called AS-1763 (docirbrutinib) for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see how well the drug works agai…

This study is testing a new oral medication called BGB-16673 for people with various B-cell blood cancers that have come back or stopped responding to prior therapies. The main goals are to find a safe and effective dose and to see how well the drug shrinks tumors and controls th…

This study is testing whether adjusting the dose of the drug ibrutinib—either alone or combined with venetoclax—can effectively control chronic lymphocytic leukemia while reducing side effects. It will enroll 320 adults who have not yet received treatment for their CLL. The goal …

This study is for veterans with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already taking a standard pill (BTKi). It tests if adding a second drug, venetoclax, for one year leads to better results than continuing the standard pill alone. After …

This study is testing a modified, gentler two-step method to prepare patients for a stem cell transplant. The goal is to reduce the risk of death from the transplant procedure itself for people with various blood cancers and disorders. Researchers are comparing two lower-intensit…

This study tests whether a new drug called BGB-16673 works better than current standard treatments for people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to previous therapy. About 150 participants in China and Taiwan wh…

This study is testing whether a combination of two drugs, acalabrutinib and obinutuzumab, can control chronic lymphocytic leukemia (CLL) for a period of time without needing continuous treatment. The main goal is to see if patients can stop all therapy and remain in remission for…

This study is testing a specific type of stem cell transplant using donated umbilical cord blood to treat patients with serious blood cancers and disorders. The procedure involves high-dose chemotherapy and radiation to wipe out the patient's diseased bone marrow before infusing …

This study aims to compare the effectiveness and safety of a new oral drug called pirtobrutinib against the standard drug ibrutinib for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It will enroll about 660 participants, some who have had pri…

This study is testing whether a daily pill called APG-2575 can help control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to standard treatments. About 75 adults whose cancer has progressed after previous therapies…

This study is for adults with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not yet needed treatment but are at high risk of their disease getting worse. It compares a cancer-fighting pill (acalabrutinib) taken alone to the same pill …

This early-stage trial is testing the safety and early effectiveness of a new type of CAR T-cell therapy called azer-cel in adults whose B-cell blood cancers have returned or not responded to prior treatments. The therapy uses donor immune cells (allogeneic) engineered to target …

This study is testing whether adding a drug called epcoritamab to standard treatment can help patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) achieve a deeper remission. The goal is to see if this combination can eliminate nearly all cancer ce…

This large, late-stage study aims to see if a new oral drug called nemtabrutinib works as well as or better than current standard drugs (ibrutinib or acalabrutinib) for people newly diagnosed with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocyt…

This study is testing a personalized cell therapy for adults with advanced B-cell leukemias that have not responded to standard drugs. Doctors take a patient's own immune cells, modify them in a lab to target a protein (CD19) found on their cancer cells, and then infuse them back…

This study is testing a personalized approach for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior treatment. It uses a combination of two approved drugs first, then checks with a very sensitive b…

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This early-stage study is testing a new, one-time gene therapy called VNX-101 for patients whose B-cell blood cancers have returned or not responded to other treatments. The therapy is designed to help the patient's own immune system continuously fight cancer cells. Researchers w…

This study is testing three different doses of an experimental drug called pirtobrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma whose cancer has returned or worsened after previous treatment with a specific type of medication called a BTK inhib…

This early-stage study is testing a new drug called AZD0486, both alone and combined with other cancer treatments, for people with advanced B-cell blood cancers that have returned or stopped responding to prior therapies. It aims to find a safe dose and see if the drug can shrink…

This study is testing if a faster, higher dose increase of a new drug called sonrotoclax is safe and tolerable for patients with certain blood cancers. It is for adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL), inclu…

This study is testing a combination of three drugs—acalabrutinib, venetoclax, and durvalumab—to see if they can help control a rare and aggressive cancer called Richter transformation. Richter transformation occurs when a slower-growing blood cancer (CLL) suddenly changes into a …

This study is testing whether a new drug called sonrotoclax works better than the current standard treatment, venetoclax, for adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to previous therapies. About 630 participants w…

This study is testing whether taking one of two drugs less often works as well as taking it continuously for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 62 participants will be randomly assigned to receive the dru…

This study is testing whether combining two oral medications, pirtobrutinib and venetoclax, can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in patients whose cancer has continued to grow despite treatment with standard BTK inhibitor drugs. The m…

This study aims to see if a new investigational drug, BGB-16673, works better and is as safe as an existing drug, pirtobrutinib, for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to prior treatment. It will involv…

This is an early-stage study testing the safety of a personalized cell therapy for adults with specific types of non-Hodgkin lymphoma that have come back or not responded to standard treatments. Doctors will modify a patient's own immune cells to better target and fight their can…

This study is testing whether adding a second drug to acalabrutinib helps achieve deeper remission in people with previously untreated chronic lymphocytic leukemia (CLL). After one year on acalabrutinib alone, participants will be randomly assigned to receive either obinutuzumab …

This study is testing a one-year treatment plan for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Participants will take the drug pirtobrutinib for six months, then add obinutuzumab for another six months, after which all trea…

This study tests whether giving pneumonia vaccines more frequently provides better protection for people with chronic lymphocytic leukemia (CLL). Currently, CLL patients get poor protection from standard vaccines and follow a 5-year schedule. Researchers will compare yearly vacci…

This study tracks healthcare costs and patient quality of life for Canadians with high-risk chronic lymphocytic leukemia. It compares starting newer treatments immediately versus waiting until symptoms appear. Researchers will follow 247 patients for up to 10 years to understand …

This study aims to learn how certain blood cancers develop and change over time. Researchers will follow up to 1,000 adults who have been diagnosed with these conditions, collecting blood and tissue samples regularly. The goal is to understand the biology of these diseases to hel…

This study aims to understand if CAR-T therapy, a powerful cancer treatment, reduces the body's long-term protection from common vaccines like measles, mumps, and tetanus. Researchers will observe 45 adults with blood cancers, measuring their antibody levels before and after CAR-…